Ardelyx announced a 19% year-over-year increase in total product revenue for Q3 2026, reaching $125.5 million, driven mainly by 23% growth in IBSRELA sales. The company holds a strong cash position of $285.3 million and completed enrollment early in its Phase 3 ACCEL clinical trial for chronic idiopathic constipation, with topline data expected in late 2027. Ardelyx reaffirmed its 2026 revenue guidance and long-term goal of $1 billion annual revenue for IBSRELA, supported by new patent protection and positive real-world data presentations. These results position Ardelyx well for future growth and value creation.
Ardelyx's third quarter 2026 financial results provide context for health sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 01:31 WIB: out of 150 priced US health-sector stocks, 110 rose and 39 fell. Notable movers include TWST at USD 140.45 (+8.84%), TXG at USD 65.76 (+6.70%), and BRKR at USD 59.22 (+6.34%).
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
